Pfizer has entered into a definitive merger agreement to acquire Anacor Pharmaceuticals, Inc. for approximately $5.2 billion in cash. Anacor’s lead asset, crisaborole, is a non-steroidal topical PDE4 inhibitor with anti-inflammatory properties currently under review by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis, or eczema. Pfizer expects to complete the acquisition in 3Q16.   In two Phase III studies, crisaborole achieved statistically significant results on all prima...